ByTrending Posts
Could Excelsior Sciences’ $95M AI Surge Redefine How…
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks, reshaping competitive timelines…
Will Novartis’s $12 Billion Avidity Deal Ignite a…
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine…
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions of experiments to…
Could the Algen Biotechnologies – AstraZeneca $555 Million…
Key Highlights / Executive Take-aways: Strategic Significance of the PartnershipThe alliance between Algen Biotechnologies and AstraZeneca marks a…
Can Takeda and Nabla Bio’s $1 Billion AI…
Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to small molecules, biologics,…
Could Cohere’s New Paris Office Accelerate AI Adoption…
Key Insights: Expanding Footprint in Europe Cohere, a Canadian AI firm known for developing large language models and…
Could Aiforia and Siemens Healthineers Transform Digital Pathology…
Key Insights: Strategic Partnership to Expand AI Pathology Aiforia Technologies Plc announced a major collaboration with Siemens Healthineers…
Can Ant Group’s AQ AI Health App Redefine…
Key Highlights Expanding AI Access in HealthcareSince its launch in June 2025, Ant Group’s AQ AI Health App…
Can GHX’s AI-Driven Supply Chain Solutions Transform How…
Key Highlights AI reshaping healthcare supply chains: Unlike retail or tech, healthcare requires flawless delivery—any delay can directly…
Trending Posts
Latest Stories
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex,…
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate
23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration…
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central
23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S.…
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally…
Gallery
